Confronto
Liraglutide vs. Mazdutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
204656-20-2
2259884-03-0
Peso molecolare
3751 g/mol
4790 g/mol
Emivita
13 h
132 h
Sequenza
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGsynthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteMeccanismo d'azione
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
4
di cui sull'uomo
4
4
Effetti registrati
3
4
Contraddizioni aperte
1
0
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Liraglutide and Mazdutide?
- Liraglutide is classified as "Metabolico", while Mazdutide is classified as "Metabolico". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Liraglutide or Mazdutide?
- The highest available evidence level is "RCT sull'uomo" for Liraglutide and "RCT sull'uomo" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Liraglutide and Mazdutide in Germany and the United States?
- Germania: Liraglutide — Su prescrizione, Mazdutide — Solo ricerca. Stati Uniti: Liraglutide — Su prescrizione, Mazdutide — Solo ricerca. These are factual summaries with source and review date on the individual pages.